Want to see CNTX full AI Analyst Report?
CNTX Stock Chart & Stats
$0.61
<$0.01(1.34%)
At close: 4:00 PM EDT
$0.61
<$0.01(1.34%)
Day’s Range― - ―
52-Week Range$0.55 - $3.62
Previous Close$0.61
Volume1.73M
Average Volume (3M)3.94M
Market Cap
$55.07M
Enterprise Value$195.14
Total Cash (Recent Filing)$54.53M
Total Debt (Recent Filing)$282.42K
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Aug 12, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding91,879,170
10 Day Avg. Volume1,601,550
30 Day Avg. Volume3,936,235
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.31
Price to Sales (P/S)0.00
P/FCF Ratio-5.30
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.67Price Target Upside828.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.39
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthContext's very low leverage and still-meaningful equity provide structural financial flexibility to fund R&D and clinical programs without immediate debt pressure. This reduces near-term refinancing risk and supports operational continuity while clinical milestones are pursued.
Full Rights To Antibody AssetsOwning irrevocable, royalty-free rights to CT-202 removes future royalty burdens and counterparty termination risk, improving long-term economics and strategic optionality for development, partnerships, or monetization of the program as it progresses to Phase 1.
Clinical Progress And Focused PipelinePositive Phase 1 signals for CTIM-76 and a clear pipeline strategy across three T cell engager programs strengthen the company's scientific positioning in solid-tumor immunotherapy and increase the chance of partner interest or milestone-driven de-risking over the next 2–6 months.
Bears Say
No Revenue And Widening LossesThe company has no product revenue and growing net losses, indicating reliance on external capital. Structural negative profitability constrains reinvestment, dilutes shareholder value through future raises, and limits internal funding capacity for multi-year development programs.
Sustained Cash BurnPersistent negative operating and free cash flow that worsened year-over-year erodes runway and forces recurrent financing. Over the medium term, continued cash burn can delay programs, require dilutive financings, or necessitate asset sales, reducing strategic flexibility.
Nasdaq Minimum Bid Price NoticeA Nasdaq deficiency notice introduces an enduring governance and market-access risk. Potential remedial actions (reverse split, financing) could alter capital structure and liquidity; failure to cure could lead to delisting, impairing investor access and partner confidence.
Context Therapeutics News
CNTX FAQ
What was Context Therapeutics’s price range in the past 12 months?
Context Therapeutics lowest stock price was $0.55 and its highest was $3.62 in the past 12 months.
What is Context Therapeutics’s market cap?
Context Therapeutics’s market cap is $55.07M.
When is Context Therapeutics’s upcoming earnings report date?
Context Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 10 days.
How were Context Therapeutics’s earnings last quarter?
Context Therapeutics released its earnings results on May 06, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.111 by $0.021.
Is Context Therapeutics overvalued?
According to Wall Street analysts Context Therapeutics’s price is currently Undervalued.
Does Context Therapeutics pay dividends?
Context Therapeutics does not currently pay dividends.
What is Context Therapeutics’s EPS estimate?
Context Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Context Therapeutics have?
Context Therapeutics has 91,879,170 shares outstanding.
What happened to Context Therapeutics’s price movement after its last earnings report?
Context Therapeutics reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.111. Following the earnings report the stock price went down -3.32%.
Which hedge fund is a major shareholder of Context Therapeutics?
Currently, no hedge funds are holding shares in CNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Context Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.67 (828.96% Upside)
$5.67 (828.96% Upside)
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.5%
Last 30 Days ▲ 13.5%
Last 30 Days ▲ 13.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-36.69%
Trailing 12-Months
Company Description
Context Therapeutics
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
CNTX Stock 12 Month Forecast
Average Price Target
$5.67
▲(828.96% Upside)
Technical Analysis
Ownership Overview
1.35% Insiders
5.78% Mutual Funds
<0.01% Other Institutional Investors
84.57% Public Companies and
Individual Investors